Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | METAP1 | P53582 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CAD | P27708 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509853 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| Hydrochloric Acid SCHEMBL11562273 | 0.98 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| Hydrochloric Acid SCHEMBL10655443 | 0.98 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| SCHEMBL11720401 | 0.92 | ALDH1A1 (0.45) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| SCHEMBL4079531 | 0.82 | ALOX15 (0.44) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| SCHEMBL8004357 | 0.82 | ALOX15 (0.44) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| SCHEMBL14769893 | 0.82 | ALOX15 (0.44) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| SCHEMBL17803395 | 0.80 | ALOX15 (0.42) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| Hydrochloric Acid SCHEMBL28058649 | 0.80 | ALOX15 (0.42) | ALDH1A1MAPTPTGS1ALOX15CPB2 | |
| SCHEMBL5250175 | 0.77 | ALDH1A1 (0.56) | ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539023-A4 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2008-12-31 | — | — | EP | claimed |
| US-20060211628-A1 | Treatment of multiple sclerosis with brain targeted anti oxidant compounds | MOR RESEARCH APPLICATIONS LTD. (IL) | 2006-09-21 | — | — | US | claimed |
| EP-1539023-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) | 2005-06-15 | — | — | EP | claimed |
| EP-0948258-A4 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2004-12-01 | — | — | EP | claimed |
| WO-2004012652-A9 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2004-06-17 | — | — | WO | claimed |
| WO-2004012652-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | claimed |
| EP-1242070-A4 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2003-05-28 | — | — | EP | claimed |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-05-01 | — | — | US | claimed |
| EP-1242070-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-25 | — | — | EP | claimed |
| EP-1059288-B1 | Process for the ring cleavage of thiazolidine derivatives | CONSORTIUM ELEKTROCHEM IND (DE) | 2002-07-17 | — | — | EP | claimed |
| US-6372912-B1 | Process for ring cleavage of thiazolidine derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 2002-04-16 | — | — | US | claimed |
| US-6369106-B1 | SULFHYDRYL CONTAINING COMPOUND AS ANTIOXIDANT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-04-09 | — | — | US | claimed |
| WO-2001047469-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-07-05 | — | — | WO | claimed |
| EP-1059288-A1 | Process for the ring cleavage of thiazolidine derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 2000-12-13 | — | — | EP | claimed |
| EP-0948258-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029375-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-09 | — | — | WO | claimed |
| EP-1539023-A4 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2008-12-31 | — | — | EP | disclosed |
| US-20060211628-A1 | Treatment of multiple sclerosis with brain targeted anti oxidant compounds | MOR RESEARCH APPLICATIONS LTD. (IL) | 2006-09-21 | — | — | US | disclosed |
| US-5874468-A | Brain targeted low molecular weight hydrophobic antioxidant compounds | YISSUM (IL) | 1999-02-23 | — | — | US | disclosed |
| WO-1998029375-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211628-A1 | Treatment of multiple sclerosis with brain targeted anti oxidant compounds | TXNRD2, TXN2, TXNRD1 | ALDH1A1 2053/4885MAPT 771/4885PTGS1 473/4885 |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | GPX4, GPX1, TXN2 | ALDH1A1 660/4885MAPT 1162/4885PTGS1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.